



ALAPIS SA announces that pursuant to its business plan, the company proceeded to the acquisition of a 49% stake at K.P.MARINOPOULOS S.A., using the funds raised from the recently completed share capital increase via rights issue. The acquisition value amounted to €18.5 mil.

K.P.MARINOPOULOS S.A. was founded in 1979 and has until today a steady growth course, aiming at providing full services and covering all needs of a modern pharmacy at quick response. It has developed a broad sales and distribution network of its pharmaceutical and parapharmaceutical products, consisting today over 2,000 points of sale.

In specific, K.P.MARINOPOULOS S.A. distributes the top quality ALEFA products (private label), all medicine available in the Greek Market, baby food and over 10,000 parapharmaceutical products.

There are a total of two hundred thirty seven employees at the company, fully trained competent enough to support and satisfy the requirements and expectations of its customers, on a daily and direct access basis.

During 2006, K.P.MARINOPOULOS S.A. consolidated turnover amounted to €266.9 mil. and EBITDA stood at €5.3 mil. For 2007, the turnover is expected to amount €315 mil. and EBITDA is expected at about €7 mil.

ALAPIS S.A. announces that all necessary information pertaining to the acquisition, pursuant to the current stock market legislation and in specific article 289 of the Athens Exchange Rules and Regulations Guide (that is the related report of the Company's Board of Directors and the related valuation report on the acquired company

by the independent audit firm), will be posted at the company's website www.alapis.eu, and will also be sent to the Athens Exchange in order to be posted at the website www.athex.gr.